Proportions of ongoing treatments and terminations grouped according to causes of terminations of individual DMARDs and COMBOs
| Discontinued | ||||||
|---|---|---|---|---|---|---|
| Inefficacy | Adverse effects | Other reasons | Remission | |||
|
DMARD/COMBO | (n (%) out of 606 starts) | (n (%) within a DMARD/COMBO) | Ongoing | |||
| GST | 131 (21.6) | 52 (39.7) | 45 (34.4) | 14 (10.7) | 9 (6.9) | 11 (8.4) |
| HCQ | 50 (8.3) | 22 (44.0) | 11 (22.0) | 8 (16.0) | 4 (8.0) | 5 (10.0) |
| SSZ | 110 (18.2) | 49 (44.5) | 28 (25.5) | 10 (9.1) | 15 (13.6) | 8 (7.3) |
| DPA | 28(4.6) | 14 (50.0) | 8 (28.6) | 3 (10.7) | 3 (10.7) | |
| AZA | 38 (6.3) | 19 (50.0) | 8 (21.1) | 8 (21.1) | 1 (2.6) | 2 (5.3) |
| CYA | 10 (1.7) | 6 (60.0) | 2 (20.0) | 2 (20.0) | ||
| MTX | 52 (8.6) | 20 (38.5) | 13 (25.0) | 6 (11.5) | 13 (25.0) | |
| AURA | 39 (6.4) | 24 (61.5) | 9 (23.1) | 1 (2.6) | 2 (5.1) | 3 (7.7) |
| CPH82 | 19 (3.1) | 12 (63.2) | 2 (10.5) | 4 (21.1) | 1 (5.3) | |
| CYP | 2 (0.3) | 1 (50.0) | 1 (50.0) | |||
| KB | 1 (0.2) | 1 (100.0) | ||||
| TENIDAP | 1 (0.2) | 1 (100.0) | ||||
| COMBO without MTX | 53 (8.7) | 31 (58.5) | 6 (11.3) | 8 (15.1) | 1 (1.9) | 7 (13.2) |
| COMBO with MTX | 72 (11.9) | 19 (26.4) | 16 (22.2) | 12 (16.7) | 25 (34.7) | |
For abbreviations, see text.